Managing the VW Emissions Crisis
February 18, 2020 All Industries Crisis Management
Earlier this year, automotive giant Volkswagen found itself facing a regulatory investigation for the results of their diesel-emissions tests. For some, the ensuing negative headlines would have broken the company. Not so for VW, which has embraced the opportunity to learn from the experience, protect shareholder value and position itself for even better days. Recorded at DirectorCorps’ Avoiding the Corporate Crisis Conference on December 3, 2019 at the Nasdaq MarketSite in NYC.
How to Get a Healthcare Deal Done
February 18, 2020 Healthcare M&A
The healthcare industry has been a fountain of dealmaking lately. Companies wanting to make acquisitions or sell businesses this year should learn from the experts.
Nasty Virus Spells Danger to Global Economy
February 18, 2020 Manufacturing Risk
Global manufacturing is expected to feel the impact of the spread of the coronavirus — not the least because China is a far larger exporter than it was during the 2003 SARS virus outbreak, according to The Wall Street Journal.
Good Governance: What’s Backed by Evidence and What’s Not
February 18, 2020 All Industries Corporate Governance
Governance always comes into sharp focus when there’s a systemwide breakdown. But a review by Stanford University law professor David Larcker and researcher Brian Tayan suggests that many of the assumptions people make about what constitutes good governance are rarely evidence-based.
Investors Push for HR Details From Public Companies
February 18, 2020 All Industries Human Capital
Investors are asking more about a company’s workforce, and companies may be forced to tell them. Last fall, the U.S. Securities and Exchange Commission proposed several changes to disclosure requirements for public companies, among them a provision to enhance disclosure about “human capital.” The rule has not been finalized.
Upcoming Event
Transactions 2020 | Health
June 3, 2020 New York New York
Be it a strategic merger or financial acquisition, the healthcare industry has experienced record-setting deal volume over the last few years. Given transactions within the pharma and biotech space to disruptions in healthcare services, we continue to see financial sponsors seeking out new paths to grow. While some believe the pace of consolidation will increase, others wonder if pricing has become too expensive and appetites for deals, overly exuberant. So is now the time to buy, sell or go public? At DirectorCorps’ annual Transactions Conference, we explore these potential paths with top executives and members of the boards of leading healthcare organizations.